Literature DB >> 18096707

An essential role for fibronectin extra type III domain A in pulmonary fibrosis.

Andrés F Muro1, Federico A Moretti, Bethany B Moore, Mei Yan, Rachelle G Atrasz, Carol A Wilke, Kevin R Flaherty, Fernando J Martinez, Jessica L Tsui, Dean Sheppard, Francisco E Baralle, Galen B Toews, Eric S White.   

Abstract

RATIONALE: Tissue fibrosis is considered a dysregulated wound-healing response. Fibronectin containing extra type III domain A (EDA) is implicated in the regulation of wound healing. EDA-containing fibronectin is deposited during wound repair, and its presence precedes that of collagen.
OBJECTIVES: To investigate the role of EDA-containing fibronectin in lung fibrogenesis.
METHODS: Primary lung fibroblasts from patients with idiopathic pulmonary fibrosis or from patients undergoing resection for lung cancer were assessed for EDA-containing fibronectin and alpha-smooth muscle actin (alpha-SMA) expression. Mice lacking the EDA domain of fibronectin and their wild-type littermates were challenged with the bleomycin model of lung fibrosis. Primary lung fibroblasts from these mice were assayed in vitro to determine the contribution of EDA-containing fibronectin to fibroblast phenotypes.
MEASUREMENTS AND MAIN RESULTS: Idiopathic pulmonary fibrosis lung fibroblasts produced markedly more EDA-containing fibronectin and alpha-SMA than control fibroblasts. EDA-null mice failed to develop significant fibrosis 21 days after bleomycin challenge, whereas wild-type controls developed the expected increase in total lung collagen. Histologic analysis of EDA-null lungs after bleomycin showed less collagen and fewer alpha-SMA-expressing myofibroblasts compared with that observed in wild-type mice. Failure to develop lung fibrosis in EDA-null mice correlated with diminished activation of latent transforming growth factor (TGF)-beta and decreased lung fibroblast responsiveness to active TGF-beta in vitro.
CONCLUSIONS: The data show that EDA-containing fibronectin is essential for the fibrotic resolution of lung injury through TGF-beta activation and responsiveness, and suggest that EDA-containing fibronectin plays a critical role in tissue fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096707      PMCID: PMC2267338          DOI: 10.1164/rccm.200708-1291OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  40 in total

Review 1.  Influence of RNA secondary structure on the pre-mRNA splicing process.

Authors:  Emanuele Buratti; Francisco E Baralle
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

2.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.

Authors:  A Nakao; M Fujii; R Matsumura; K Kumano; Y Saito; K Miyazono; I Iwamoto
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

3.  Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10).

Authors:  Eric S White; Rachelle G Atrasz; Biao Hu; Sem H Phan; Vuk Stambolic; Tak W Mak; Cory M Hogaboam; Kevin R Flaherty; Fernando J Martinez; Christopher D Kontos; Galen B Toews
Journal:  Am J Respir Crit Care Med       Date:  2005-09-22       Impact factor: 21.405

4.  Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene.

Authors:  H A Jaffe; Z Gao; Y Mori; L Li; J Varga
Journal:  Exp Lung Res       Date:  1999 Apr-May       Impact factor: 2.459

5.  Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis.

Authors:  Wataru Matsuyama; Masaki Watanabe; Yuko Shirahama; Hideo Mitsuyama; Ikkou Higashimoto; Mitsuhiro Osame; Kimiyoshi Arimura
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

6.  PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.

Authors:  Heather A Burgess; Louis Eugene Daugherty; Thomas H Thatcher; Heather F Lakatos; Denise M Ray; Michelle Redonnet; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-02-25       Impact factor: 5.464

7.  Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes.

Authors:  T H Sisson; N Hattori; Y Xu; R H Simon
Journal:  Hum Gene Ther       Date:  1999-09-20       Impact factor: 5.695

8.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Authors:  J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

9.  Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells.

Authors:  Stephen G Ball; C Adrian Shuttleworth; Cay M Kielty
Journal:  Int J Biochem Cell Biol       Date:  2006-09-24       Impact factor: 5.085

10.  The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1.

Authors:  G Serini; M L Bochaton-Piallat; P Ropraz; A Geinoz; L Borsi; L Zardi; G Gabbiani
Journal:  J Cell Biol       Date:  1998-08-10       Impact factor: 10.539

View more
  126 in total

1.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice.

Authors:  Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  Fibronectin: functional character and role in alcoholic liver disease.

Authors:  Razia S Aziz-Seible; Carol A Casey
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 3.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 4.  Extracellular matrix dynamics and fetal membrane rupture.

Authors:  Jerome F Strauss
Journal:  Reprod Sci       Date:  2012-01-19       Impact factor: 3.060

Review 5.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

6.  EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling.

Authors:  Martin Kohan; Andres F Muro; Eric S White; Neville Berkman
Journal:  FASEB J       Date:  2010-07-19       Impact factor: 5.191

Review 7.  Role of innate immune system in systemic sclerosis.

Authors:  Nicola Fullard; Steven O'Reilly
Journal:  Semin Immunopathol       Date:  2015-07-10       Impact factor: 9.623

8.  Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia.

Authors:  Manish Jain; Nirav Dhanesha; Prakash Doddapattar; Mehul R Chorawala; Manasa K Nayak; Anne Cornelissen; Liang Guo; Aloke V Finn; Steven R Lentz; Anil K Chauhan
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 9.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

10.  Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis.

Authors:  Christina Cho; Rhiannon Kelsh-Lasher; Anthony Ambesi; Paula J McKeown-Longo
Journal:  Curr Top Pept Protein Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.